相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
Lucien Noens et al.
BLOOD (2009)
Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group
Mari Sakai et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2009)
Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels
Donna L. Forrest et al.
LEUKEMIA RESEARCH (2009)
Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase
Toru Kiguchi et al.
LEUKEMIA RESEARCH (2009)
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
Richard A. Larson et al.
BLOOD (2008)
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
Stephane Picard et al.
BLOOD (2007)
Relationship between daily dose of imatinib per square meter and its plasma concentration in patients with chronic-phase chronic myeloid leukemia (CML)
Akira Horikoshi et al.
LEUKEMIA RESEARCH (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML)
C Walz et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2006)
Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry
Karine Titier et al.
THERAPEUTIC DRUG MONITORING (2005)
Clinical pharmacokinetics of imatinib
B Peng et al.
CLINICAL PHARMACOKINETICS (2005)
Absolute bioavailability of imatinib (Glivec®) orally versus intravenous infusion
B Peng et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Optimizing treatment of chronic myeloid leukemia: A rational approach
RM Stone
ONCOLOGIST (2004)
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
TP Hughes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models
FX Mahon et al.
BLOOD (2003)
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
NJ Donato et al.
BLOOD (2003)
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses
HM Kantarjian et al.
BLOOD (2003)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
分享论文
